EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Atypical Dermatophytosis in Patients Treated by JAK Inhibitors

Jen A. Barak Levitt, Nurit Kulish, Mira Hamed, Michael Ziv, Eran Cohen Barak

Experimental Dermatology · 2026-03 · 35 (3)

DOI: 10.1111/exd.70223 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Janus kinase (JAK) inhibitors are commonly used to treat immune‐mediated diseases by modulating the JAK–STAT signalling pathway. While these agents are therapeutically effective, they may also impair immunity, including antifungal response. Here, we present five cases of atypical dermatophyte infections in patients treated with baricitinib or upadacitinib. Their clinical presentations and treatment regimens were summarised to highlight the atypical features and the presumed effects of JAK inhibitors. Patients presented with erythematous indurated plaques, clustered firm papules, and widespread thin plaques with scaling and erosions. PCR and fungal cultures confirmed infections with Trichophyton tonsurans , Trichophyton rubrum , Trichophyton verrucosum , and Microsporum canis . Treatment with systemic antifungal agents such as terbinafine, itraconazole, and griseofulvin was effective. In some cases, the dosage of JAK inhibitors was reduced during antifungal therapy. Clinicians should be vigilant for cutaneous fungal infections in JAK inhibitor‐treated patients with new rashes. The immunomodulatory effect of JAK inhibitors may attenuate the clinical manifestation and lead to delayed recognition of dermatophytosis.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →